M[uscle]{.smallcaps} contraction is the result of a series of protein--protein interactions and conformational changes that culminate in ATP-dependent movement of the myosin head of the thick filament when it is attached to actin of the thin filament. The action of the myosin head slides the thin filament relative to the thick filament, causing sarcomere shortening. Thin filaments are normally inhibited from interacting with thick filaments due to blockage of the myosin binding sites on actin by a strand of tropomyosin molecules, and possibly by the troponin I protein of the thin-filament based troponin complex. The inhibition is relieved by release of calcium ions from internal stores following neural activity. Ca^2+^ binds to troponin C protein, reconfiguring the troponin T--based interaction of the entire troponin complex with tropomyosin. The resulting movement of the tropomyosin strand from its inhibitory position permits the myosin crossbridge to bind to the thin filament. For a recent review, see [@B43].

There are numerous conformational rearrangements involved in thin-filament regulation of the crossbridge cycle ([@B9]). Multiple Ca^2+^-induced changes in interaction among subunits of the troponin complex and between troponin and tropomyosin occur, although the details of the structural role of the troponin complex in this regulation are not known. Not only does tropomyosin shift during Ca^2+^ activation of the thin filament, but the actin monomer changes conformation ([@B1]). Further, binding of the myosin head to the thin filament is a cooperative process that involves progressive tropomyosin movement ([@B51]). The first myosin heads bind weakly to actin and interact with tropomyosin to push it further away from myosin binding sites on actin. This leads to a decreased duration of the ATP cycle, i.e., a fully on state ([@B25]; [@B26]). Understanding the details of the contractile cycle is important for defining the mechanisms of human diseases, such as familial hypertrophic cardiomyopathy, where mutations in a number of sarcomeric contractile proteins can result in aberrant contractile properties and muscle hypertrophy ([@B52]; [@B46]).

Some success in mapping precise interaction sites of various contractile apparatus components has resulted from electron microscopy/image reconstruction, and from biochemical assays that assess interaction between intact proteins, proteolytic fragments, and expressed recombinant peptides. These studies are supplemented by determinations of atomic structure of contractile proteins that indicate the location of putative binding sites in particular conformational states. For instance, it has been shown recently that an NH~2~-terminal α-helical region of troponin I binds to troponin C at low Ca^2+^ conditions ([@B50]). It is proposed that Ca^2+^ binding to troponin C releases this troponin I region and allows binding of an inhibitory region of troponin I, thereby allowing actomyosin interaction ([@B47]; [@B50]). It is important to note, however, that in vitro approaches represent a trade off between structural resolution and biological significance of derived conclusions. The inhibitory role of troponin I is a case in point. Inhibitory properties have been ascribed to the fragment between residues 104--115. However, this fragment\'s inhibiting efficiency is lower than the entire 1--116 fragment and this, in turn, is less inhibitory than the whole molecule ([@B47]; [@B49]).

An alternative method to assessing functional interactions of proteins during the contractile cycle involves genetic analysis, i.e., disrupting muscle function by mutating a particular contractile protein and searching for suppressor mutations that restore function. This is a particularly powerful approach in that interactions relevant to muscle function in vivo are clarified. In principle, suppressor mutations reveal sites of specific protein--protein interactions that are important to myofibril assembly and/or function. It is also possible that suppressor mutations work by less direct mechanisms, such as through interactions with an intermediary component of the contractile apparatus, or by a general change in protein function that compensates for the original mutation in a less specific way. The suppressor mutation approach has been applied most successfully to mapping muscle protein interactions in *Caenorhabditis elegans* ([@B12]; [@B27]; [@B33]; [@B11]).

[@B35] described the isolation of suppressor mutations in *Drosophila melanogaster* for a particular point mutation of troponin I, the inhibitory subunit of the troponin complex. These suppressors prevent the heldup wings phenotype that arises from severe defects in the indirect flight muscles of the troponin I mutant. One suppressor is within the mutated troponin I protein itself ([@B35]). Four others are mapped to the second chromosome. Determination of mutant gene(s) that act to suppress troponin I defect, and definition of the precise location of mutations should reveal protein--protein interactions important to muscle function in vivo.

In this paper, we show that the four genetic suppressors of a *Drosophila* troponin I point mutation are within the myosin heavy chain (MHC)^1^. We determine molecular alterations in the myosin molecule and map these on the three-dimensional structure of globular head in an effort to understand the molecular basis of suppression. We show that observed suppression is allele-specific, i.e., it is dependent on a specific mutated residue in troponin I and particular sites within MHC. We elucidate the degree of phenotypic suppression observed in indirect flight muscles of adult flies using light and electron microscopy, and demonstrate that different myosin suppressor alleles suppress the troponin defects to different degrees. Finally, we discuss the possibility that our work reveals an interaction between MHC and troponin I, a prospect not previously proposed based on structural or biochemical studies.

Materials and Methods {#MaterialsMethods}
=====================

Isolation, Mapping, and Sequencing of Suppressor Mutations
----------------------------------------------------------

Isolation of dominant suppressors of *heldup^2^* was described in [@B35]. In brief, adult *hdp^2^* males were mutagenized with ethyl-methane sulfonate (EMS) according to standard procedures, and crossed to females of the genotype *C(1)M3/Y*;*Sco/CyO* or *C(1)M3/Y*;*TM1/TM3*. Male offspring with near normal wing position, instead of the expected heldup wings, were crossed individually to balancer stocks to identify the chromosome containing the suppressor. Stocks with a series of recessive markers were used to determine the map position of each suppressor on a particular chromosome based upon recombination between markers. Each isolated suppressor should be designated as *Su(hdp^2^)D* followed by an identification number. For brevity, they are referred to as *D* mutations in the text. As per standard practice, gene abbreviations are designated in italics and proteins are in capital Roman type.

We obtained recessive--lethal, homozygous suppressor strain embryos for DNA amplification and sequencing by using a second chromosome balancer line *(CyO y^+^)* marked with the *yellow^+^* gene (*y^+^*; [@B24]) in combination with an X chromosome marked with the *y* and *w* (white eye) mutations. To this end, *hdp^2^*;*D* mutation/*CyO* males were mated with *y w*;*CyO y^+^/Bc Elp* females. Male offspring of genotype *y w*;*D* mutation/*CyO y^+^* were backcrossed to *y w*;*CyO y^+^/Bc Elp* females. Resulting males and females of the *y w*;*D* mutation/*CyO y^+^* genotype were mated to produce a stable stock. Embryos with dark mouth hooks carry one or two copies of the second chromosome marked with *CyO y^+^*, while homozygotes for the *D* suppressor mutation display yellow mouth hooks.

Genomic DNA was extracted from homozygous embryos of each suppressor mutant according to the method of [@B17]. 60 embryos were frozen in an Eppendorf tube and stored at −80°C for at least 1 h. 40 μl of single fly homogenization buffer (10 mM Tris-HCl, pH 7.5, 60 mM NaCl, 50 mM EDTA, 150 μM spermine, 150 μM spermidine) were added and the samples were ground with a plastic pestle. 40 μl of single fly lysis buffer (1.25% \[wt/vol\] SDS, 300 mM Tris-HCl, pH 8, 100 mM EDTA, 5% \[wt/vol\] sucrose, 0.75% freshly added diethyl pyrocarbonate) were added. The mixture was incubated for 30 min at 60°C. The sample was cooled to room temperature and 12 μl of 8 M potassium acetate was added. After cooling on ice for 45 min, debris was pelleted by 1 min centrifugation in a microfuge. Supernatant was removed to a fresh tube and 200 μl of 100% ethanol was added. DNA was precipitated at room temperature for 10 min and pelleted in a microfuge for 10 min. The sample was washed with 80% ethanol and vacuum dried. The pellet was resuspended in 60 μl TE (10 mM Tris-HCl, pH 8, 1 mM EDTA).

Genomic DNA from each mutant was used in PCR to generate 11 fragments that cover the entire coding region, plus flanking introns of the *Mhc* gene. The following oligonucleotide primers were used for amplification (sequences given for noncoding strand in a 5′ to 3′ orientation): 1, ATGCCGAAGCCAGTCGCAAAT (position 1924), GGAATTCGATACGGATGAATTTACC (position 4141); 2, TAAGCTTGAAGACCGATGAGGCC (position 3948), ATAGCCGTCACTACATAGAGC (position 5941); 3, TTATGTTCTTCTTGCTAAACC (position 6456), ATCTGACTAAAATCCTCAGA (position 8185); 4, GATACACTGCAGCACTAT (position 8367), TGATCGGAGGCCTTGGGGAAC (position 10131); 5, GTTCCCCAAGGCCTCCGATCA (position 10131), GTGTGGGGATTCAATTGAAAG (position 11087); 6, GGAATCAAAAACGAACTCTAC (position 11206), CTAATTGTGGAAGGAGC (position 11818); 7, GTTAAGATCAACTGTAACTAA (position 12206), AGACCCAGGCTGGTCTCGTT (position 14095); 8, CTTCAGCCCGAATCGACCGCC (position 15455), TCAGATCTCTCTATCTCGAT (position 16958); 9, TTGAAGGATCTACAGTTTACA (position 16959), GGGTGACAGACGCTGCTTGGT (position 18365); 10, GTCCCAGGTGTCTCAGCTGT (position 18045), GGCGGGCGGCATCGACCATAG (position 19512); and 11, TGCGTCGTGAGAACAAGAACC (position 18653), TATTACTCTCTTGTTTT (position 20368). Each PCR sample contained 5 μl of genomic DNA, 20 μl of 10× PCR buffer (Promega Corp.), 20 μl of 5 μM solutions of each dNTP (80 μl total), 16 μl of 25 mM MgCl~2~, 100 pmol each of two primers, 0.8 μl of Taq polymerase (Promega Corp.), and was brought to a total volume of 200 μl with distilled H~2~O. Paraffin oil was placed on top of the sample to prevent evaporation, and DNA was amplified in an Ericomp thermocycler as follows: one cycle at 95°C for 1 min, 45°C for 2 min, 72°C for 40 min; 28 cycles at 95°C for 1 min, 45°C for 2 min, 72°C for 6 min; and one cycle at 95°C for 1 min, 45°C for 2 min, 72°C for 15 min. Paraffin oil was then removed and DNA was chloroform extracted and precipitated.

PCR products were cloned before sequencing. Amplified products were separated by agarose gel electrophoresis, isolated using GeneClean (Bio 101), and blunt ends were created with the Klenow fragment of *Escherichia coli* DNA polymerase I ([@B41]). Each fragment was cloned into the EcoRV site of pKS plasmid (Stratagene) and DNA sequencing was performed using a Sequenase kit (United States Biochemicals) or on an automated DNA sequencer (Applied Biosystems).

Reverse Transcription and Amplification of Mhc mRNA
---------------------------------------------------

First strand synthesis of cDNA was performed using 1 μg of total RNA (isolated as described in [@B14]), 100 pmol of 3′ primer (TGATCGGAGGCCTTGGGGAAC, position 10131), 1.4 μl of 5× first strand buffer (250 mM Tris, pH 8.5, 375 mM KCl, 5 mM MgCl~2~, 50 mM dithiothreitol), brought to a total volume of 7 μl with distilled H~2~O. The mixture was placed in boiling water for 30 s, then allowed to cool to 37°C. 1 μl of Inhibitase (1 U/μl; Promega Corp.) was then added along with 0.5 μl of each dNTP at 10 mM. Then 0.6 μl of 5× first strand buffer was added plus 0.5 μl of distilled H~2~O. The reaction was started by addition of 1.0 μl of M-MLv reverse transcriptase (100 U/μl; GIBCO BRL) and the sample was incubated at 37°C for 1.5 h. The reaction was terminated on ice by adding 20 μl of 0.3 M NaOH/0.03 M EDTA. RNA was hydrolyzed at 60°C for 1 h. The solution was neutralized by adding 3.4 μl of 3 M sodium acetate, pH 5.2, and cDNA was precipitated with 2.5 vol of 100% ethanol. After centrifugation in the microfuge for 15 min at 4°C, the DNA pellet was washed with 80% ethanol and vacuum dried. The sample was resuspended in 10 μl distilled H~2~O. Half the sample was amplified using the 3′ primer at position 10131 and 5′ primer GGCTGGTGCTGATATTGAGA (position 4182), as described for genomic DNA above.

In Situ Hybridization
---------------------

Slides were cleaned by thorough washing with liquid hand soap, then treated with subbing solution (0.5% gelatin, 0.05% chrome alum). Slides were dried overnight in a dust-free environment. Tissue was prepared by embedding whole flies (with wings removed) in OCT compound and freezing on dry ice. Frozen tissue sections (8--16 μm) were taken using a microtome. These were placed onto treated slides and allowed to dry. Tissue was fixed with 4% paraformaldehyde for 20 min and then washed three times in 1× PBT (1.3 M NaCl, 0.07 M Na~2~HPO~4~, 0.03 M NaH~2~PO~4~, 1% Tween 20). Sections were then treated with 50 μg/ml proteinase K in PBT for 3 min. This was followed by treatment with 2 mg/ml glycine in PBT for 1 min (repeated once). Slides were washed in PBS (1.3 M NaCl, 0.07 M Na~2~HPO~4~, 0.03 M NaH~2~PO~4~) for 1 min and placed in 4% paraformaldehyde for 20 min. This was followed by two washes with PBS for 5 min each. The samples were dehydrated in 30% ethanol, 50% ethanol, 70% ethanol, 80% ethanol, 95% ethanol, 100% ethanol (5 min each), and placed under the vacuum for 40 min.

Transcription of digoxigenin-labeled probes was according to the procedure provided in Genius 3 Kit (Boehringer Mannheim). Antisense probes from each copy of exon 7 were prepared from the following fragments that had been cloned into a plasmid containing a T3 or T7 RNA polymerase binding site: exon 7a, XbaI (4568) to HindIII (4940); exon 7b, HindIII (4940) to HindIII (5300); exon 7c, Hind III (5300) to EcoRV (5900); exon 7d, EcoRV (5900) to EcoRI (6600). 1 μg of RNA probe was added to 25 μl of 10 mg/ml tRNA and brought to a total volume of 100 μl with distilled H~2~O. The probe was denatured by heating at 75°C for 10 min.

Hybridization was carried out by adding the denatured probe to 400 μl of hybridization buffer (50% formamide, 10% dextran sulfate, 0.3 M NaCl, 10 mM Tris-HCl, pH 8, 1 mM EDTA, 0.1% Tween 20, 50 μg/ml heparin, 1× Denhardt\'s solution). 100 μl of the probe in hybridization solution were placed onto each slide. Slides were covered with a plastic sealer (HybriWell, Research Products International) and placed in a sealed box. Hybridization was allowed to proceed for at least 18 h at 56°C.

After hybridization, slides were washed with 4× SSC (twice for 10 min each). This was followed by RNase A treatment (20 μg/ml in 0.5 M NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA) to remove single-stranded probe for 30 min at 37°C. Slides were washed in PBT for 5 min (repeated once), and then incubated with antibody conjugate at a ratio of 1:500 in PBT plus 5% normal goat serum for 120 min. Unbound antibody was washed off with buffer 3 (100 mM Tris, pH 9.53, 100 mM NaCl, 50 mM MgCl~2~) for 5 min. This was repeated. Color reaction buffer was prepared by adding 20 ml of buffer 3 to 100 μl of NBT and 75 μl of X phosphate. This reaction was allowed to proceed for at least 1 h and as long as overnight. The reaction was stopped by rinsing in H~2~O.

Protein Analysis
----------------

One-dimensional SDS-PAGE was performed by the method of [@B20]. Upper thoraces from 10 flies were dissected, homogenized in 100 μl sample buffer and boiled. Samples (10 μl) were loaded on gels containing 9.5% acrylamide. After staining in Coomassie blue, scanning was performed using a Molecular Dynamics densitometer. MHC levels were normalized to actin levels within the same lane to account for differences in protein loading levels.

Flight Testing
--------------

Flight testing was performed using the method of [@B8] on young (2-d-old flies).

Microscopy
----------

For transmission electron microscopy, flies were dissected according to the protocol of [@B34]. Once the heads, wings, and abdomens were removed, thoraces were fixed overnight at 4°C in 4% paraformaldehyde, 1% glutaraldehyde in 0.1 M phosphate buffer, pH 7.2. The dorsolongitudinal muscles (DLMs) were dissected from the thoraces, washed several times in buffer, and postfixed in 2% OsO~4~ in buffer for 45 min at 4°C in the dark. After dehydration, DLMs were embedded in Araldite resin. Silver sections (60--70 nm) were cut on a Reichert Ultracut E ultramicrotome, collected on Formvar-coated grids, and counterstained with uranyl acetate (10 min) and lead citrate (10 min). Micrographs were obtained using a JEOL 1200 EX electron microscope. Morphological analysis at the light microscope level was carried out on paraffin-embedded samples stained with Toluidine blue ([@B35]).

Results {#Results}
=======

Phenotypic Analysis of Dorsolongitudinal Muscles in Normal Flies and heldup^2^ Troponin I Mutants
-------------------------------------------------------------------------------------------------

The DLMs are composed of six fibers (a--f) attached to the anterior and posterior sides of the thorax (Fig. [1](#F1){ref-type="fig"} A). The DLM fibers, like the opposing dorsoventral indirect flight muscles, are termed fibrillar muscles. This is because each fiber contains several hundred myofibrils that can be easily teased apart. Individual fibrils are subdivided by transverse bands of electron dense material, the Z bands, that define the unit of contraction, the sarcomere (Fig. [1](#F1){ref-type="fig"} B). In a transverse view, the circular fibril contains a crystalline-like array of thick and thin filaments that is arranged in a 1:6 hexagonal pattern (Fig. [1](#F1){ref-type="fig"} C). In the normal strain used here, Canton-S (CS), ∼1,000 thick and 2,000 thin filaments accumulate in each fibril. These numbers are fairly constant within a muscle showing only a 5% variability in DLM muscle (a) of our CS stock. Note, however, that other normal strains may exhibit up to 1,500 thick filaments per fibril.

In the troponin I mutant *heldup^2^*, the six DLMs appear torn apart from the center (Fig. [1](#F1){ref-type="fig"} D). In the remaining muscle material, near the attachment sites, the sarcomere length is 40% reduced and the thick--thin filament pattern is destroyed mostly due to the collapse of thin filaments (Fig. [1](#F1){ref-type="fig"}, E and F). It appears as if the mutant muscles were clamped in a state of hypercontraction. The mutation *hdp^2^* is a single amino acid change, ^Ala^55^Val^, affecting all known isoforms of troponin I ([@B3]; our unpublished data). This corresponds to residue 25 in rabbit skeletal muscle troponin I (see [@B50]).

D Suppressors on Chromosome II are Mhc Mutations
------------------------------------------------

To identify molecular interactions between muscle proteins and troponin I, we screened for mutations that suppress the heldup wing position of the troponin I *hdp^2^* mutation and isolated four *D* mutations that map to chromosome II ([@B35]). We employed meiotic recombination to discern their locations on the second chromosome, and found they map between markers *rd* and *pr*. Further, we localized recessive lethality associated with mutations *D41*, *45,* and *62* to the interval uncovered by *Df(2)H20*. This deficiency removes polytene chromosome regions 36A8--36A9;36F1 and contains the *myosin heavy chain (Mhc)* gene.

To determine whether the suppressor mutations are *Mhc* alleles, we performed genetic complementation tests with known *Mhc* alleles (for details on these alleles, see [@B23]). We crossed each of the *D*-suppressor mutants to a null mutant (*Mhc^1^*), a hypomorphic mutant (*Mhc^2^*), and several point mutants (*Mhc^5^*, *Mhc^6^*, *Mhc^8^*). *Mhc^1^*, *Mhc^2^*, and *Mhc^8^* are recessive lethal alleles, while *Mhc^5^* and *Mhc^6^* are viable as homozygotes. Our results show that the *D*-suppressor mutants are likely to be *Mhc* alleles, since none of the suppressors produced progeny over *Mhc* null or hypomorphic alleles, except for *D1* which occasionally was viable in combination with *Mhc^1^*. The suppressors produced viable progeny in combination with the various point mutations, except that *D1* is lethal in combination with *Mhc^5^*, *D41* is lethal with *Mhc^8^,* and *D62* produces very few viable adults in combination with *Mhc^8^*. These data demonstrate interaction, and likely allelism, between the *D*-suppressor mutants and *Mhc*.

Since *Mhc* null alleles are recessive lethal ([@B31]), as are three of the four *D*-series suppressor mutants, it is important to determine whether the latter exert their suppression effect through failure to accumulate MHC. We determined whether MHC protein accumulates in the suppressor strains by crossing each to *Mhc^10^* and measuring MHC levels in upper thoraces of heterozygotes. *Mhc^10^* adults fail to accumulate MHC in the jump and indirect flight muscles due to a mutation in an alternative exon specifically used in these muscle types ([@B32]). Each of the *D/Mhc^10^* heterozygotes accumulate more MHC than *Mhc^10^/Mhc^10^* adults, but less than +/*Mhc^10^* individuals (Table [I](#TI){ref-type="table"}). This indicates that suppressor mutations produce stable MHC protein. While the suppressor mutants accumulate only ∼65--85% as much MHC as flies carrying one copy of wild-type *Mhc* gene, it is clear that suppressor alleles are not null mutations for *Mhc*. It is also noteworthy that *Mhc* missense mutations that cause flight muscle dysfunction typically result in less than wild-type levels of MHC accumulation ([@B28]; [@B19]).

To demonstrate that each suppressor mutation resides within *Mhc*, and to determine their molecular lesions, we cloned and sequenced the *Mhc* gene from homozygous embryos of each strain. We found that each suppressor strain has a discrete region of the *Mhc* coding sequence altered, and all mutations affect the head domain (S1 fragment) of the myosin molecule. We mapped encoded aberrations onto the three-dimensional map of chicken myosin head (Fig. [2](#F2){ref-type="fig"}). Amino acid identity between *Drosophila* and chicken myosin is high, and the atomic resolution crystal structure of the chicken molecule ([@B37]) serves as an excellent model for visualizing *Drosophila* alternative coding regions and mutations ([@B4]).

*D1* is a point mutation in exon 10 (A→ G), changing amino acid 625 (chicken MHC numbering system) from Asp to Gly (Table [I](#TI){ref-type="table"}). This mutation affects an amino acid at the base of the second loop of the molecule (Fig. [2](#F2){ref-type="fig"}). This loop is involved in actin binding ([@B29]; [@B44]; [@B36],b; [@B48]; [@B40]). If the mutation affects the mobility of the loop, it could dampen acto-myosin interaction.

Mutation *D62* also affects exon 10, and is a 24-bp in-frame deletion starting at amino acid 638 (Table [I](#TI){ref-type="table"}). Like *D1*, this mutation affects the loop that binds actin. It removes eight amino acids within the loop and clearly would be expected to affect actomyosin interaction. The loop, which runs from residue 627 to 646, is not visible in Fig. [2](#F2){ref-type="fig"} due to its flexible nature ([@B37]).

Mutation *D45* is a point mutation in exon 5 (G→ A), changing amino acid 261 from Ala to Thr (Table [I](#TI){ref-type="table"}). This amino acid is in the general vicinity of ATP entry and the ATP binding site (Fig. [2](#F2){ref-type="fig"}). However, it is on the surface of the molecule, away from direct interactions with the nucleotide. It is located very close to loop 1 of the molecule (residues 204--216), which is not visible in the structure. This loop is important for regulating nucleotide entry and exit from the ATP binding pocket ([@B30]; [@B45]).

Mutation *D41* is a 2-bp insertion into exon 7a, interrupting amino acid codon 328. It places this alternative exon out of frame and inserts a stop codon (Table [I](#TI){ref-type="table"}). The mutation also produces a potential 5′ splice junction, GTAGCT. This could disrupt alternative splicing. To study this, we used RT-PCR to amplify the exon 7 region in adult upper thoraces from this mutant. Since this mutation is recessive lethal, the thoraces were taken from *D41/Mhc^10^* organisms (note that *Mhc^10^* RNA fails to accumulate in fly thoraces due to a splicing defect; [@B5]). We cloned the PCR products from *D41/ Mhc^10^* heterozygotes and analyzed a number of clones by DNA sequencing or restriction enzyme digestion. Normally exon 7d is used in indirect flight muscles ([@B13]), which make up the bulk of the thorax. We found this to be the case in all 17 clones analyzed from wild-type thoraces. However, we observed an extreme reduction in exon 7d usage, replaced by in-frame inclusion of exons 7b or 7c, in clones of *Mhc* PCR products from thoraces of *D41/Mhc^10^* organisms (1 exon 7b, 13 exon 7c, and 4 exon 7d). Thus, the insertion of a splice junction in exon 7a appears to disrupt the alternative splicing process.

We next used in situ hybridization to investigate the possibility of tissue-specific alternative splicing disruption in thoracic musculature of *D41* adults. Alternative exon-specific probes were prepared and hybridized to sections of young adults, either wild-type or *D41/Mhc^10^* mutant. The hybridization results clearly showed that exon 7d accumulates in indirect flight muscles of wild-type, but is below detectable levels in *D41* indirect flight muscles (Fig. [3](#F3){ref-type="fig"}). High levels of exon 7c accumulate in *D41* indirect flight muscles, but no trace of this exon is detected in wild-type indirect flight muscle transcripts. Thus, the unusual effect of the mutation is to disrupt the alternative splicing apparatus through the introduction of a 5′ splice site, resulting in use of a different alternative exon than is normally employed in indirect flight muscles. Exon 7 encodes a region at the lip of the nucleotide binding pocket (light blue in Fig. [2](#F2){ref-type="fig"}). It is possible that using the wrong version of this alternative exon disrupts MHC function by changing nucleotide affinity and disrupting the ATPase cycle.

We also studied use of the aberrant version of exon 7a in the *D41* mutant. In wild-type embryos, alternative exon 7a is abundantly expressed in body wall muscles (Zhang and Bernstein, manuscript in preparation). Our RT-PCR analysis of RNA from wild-type embryos confirmed that this is the major exon 7 version used at this stage (16 clones examined) and showed that exon 7a is incorporated in all reverse transcribed mRNAs studied from homozygous *D41* embryos (14 clones). The normal splice junction is used in the mutant. This would result in premature termination of translation due to the stop codon described above, and explains the recessive lethality of the mutation. The suppressive effect of the *D41* mutation upon the *hdp^2^* phenotype, however, appears to result from misexpression of exon 7c in the indirect flight muscles.

Functional and Structural Effects of D Suppressors
--------------------------------------------------

We examined the degree of rescue of *hdp^2^* phenotypes by each suppressor mutation that maps within the head domain of MHC. While the suppressed wing position phenotype is evident in all *hdp^2^*;*D/+* males, none can jump or fly under standard criteria ([@B35]). We analyzed the structural effects of the suppressors in *hdp^2^*;*D/+* males at light and electron microscopic levels (Fig. [4](#F4){ref-type="fig"}). In general, the organization of the six DLMs is restored with similar efficiency by the four *D* mutations. However, the e and f muscles, their posterior region in particular, are still very sensitive to contraction, and appear grossly abnormal at 3--5 d (Fig. [4](#F4){ref-type="fig"}, A, E, I, and M).

Wild-type sarcomere structure and length in *hdp^2^* individuals is recovered to different degrees as a result of each *D* mutation. The M line reappears in all four cases but the sarcomere length is best restored by *D41*. Organization of Z bands is better in *D1* and *D62* than with the other two alleles (Fig. [4](#F4){ref-type="fig"}, B, F, J, and N). The number of thick filaments per fibril averages 950 in *D45*, 830 in *D41*, 750 in *D62,* and 650 in *D1*. These are 5--35% below normal. In spite of nearly normal numbers of thick filaments, *D41* fibrils appear particularly unstable at the periphery, where the lattice collapses (Fig. [4](#F4){ref-type="fig"} K). These features, and those reported for second site suppressor *D3* ([@B35]), point toward differential sensitivity of the center versus the periphery of the fibril. The arrangement of thick and thin filaments found in the suppressed condition include various types of abnormalities, e.g., absence of a thick filament, excess thin filaments, substitution of thick by thin filaments, or doublets of thick filaments (Fig. [4](#F4){ref-type="fig"}, D, H, L, and P). These perturbations do not induce major defects in the surrounding structure.

We also studied the effects of the *D*-series suppressors upon flight muscle function in the absence of *hdp^2^* mutation. The suppressors show dominant effects upon flight muscle function (Table [II](#TII){ref-type="table"}). *D1* is least disruptive, with 85% of adults flying upward or horizontally, compared with 90% in wild-type. *D62* is most disruptive, with only 16% flying upward or horizontally (Table [II](#TII){ref-type="table"}). We determined whether the wild-type *Mhc* gene could rescue defects in flight ability by crossing each suppressor strain to a stock containing an *Mhc* transgene ([@B6]). No rescue was observed (Table [II](#TII){ref-type="table"}), consistent with our observation that suppressor alleles produce stable MHC proteins which interfere with myofibril function.

Allelic Interactions and Specificity of Suppressed Phenotypes
-------------------------------------------------------------

To investigate the unique nature of each suppressor\'s action, we tested all pairwise combinations of *D* mutants in a *hdp^2^* male background. We expect an additive or synergistic effect when two *Mhc* mutations are suppressed by different mechanisms. If the same mechanism of suppression is employed by two different suppressors, we expect a phenotype similar to that of flies with a single suppressor. Only combinations over *D1* resulted in viable adults, and the structure of the resulting a or b fiber from their DLMs is illustrated in Fig. [5](#F5){ref-type="fig"}. In the three cases of transheterozygotes, muscle structure is closer to normal than in each of the four independent *D* mutants. In addition, *hdp^2^*;*D1/ D41* flies are able to jump while the *D/+* mutants are not. Interestingly, the *D1/D62* combination exhibits a high number of double thick filaments. This abnormal feature is rarely seen in *D1/+* or *D62/+* muscles. The synergistic effects of *D1* suppression observed in combination with each of the other alleles suggests that *D1* employs a unique suppression mechanism compared with the other *D*-series *Mhc* alleles.

Next, we tested whether other *Mhc* alleles are capable of suppression of *hdp^2^* phenotypes, either alone or in combination with *D*-series suppressors (Table [III](#TIII){ref-type="table"}). Three point mutations and the *H20* deficiency chromosome were chosen to observe effects of specific amino acid changes or reduction in MHC levels upon the *hdp^2^* phenotypes. [@B16] had previously described a negative interaction between two of these alleles (*Mhc^5^* and *Mhc^8^*) and *hdp^2^*. Our data corroborated that *Mhc^5^* is lethal in combination with *hdp^2^/Y*, but showed a reduced viability, rather than complete lethality, between *Mhc^8^* and *hdp^2^/Y* (Table [III](#TIII){ref-type="table"}). The heldup phenotype was maintained in viable organisms in the latter case. This was also seen for the *Mhc^6^* point mutation and the deficiency chromosome. These results indicate that underexpression of MHC or non-*D* point mutations known to cause a dominant flightless phenotype do not suppress the heldup wing phenotype associated with specific troponin I allele *hdp^2^*.

We studied the non-suppressor *Mhc* point mutants in more detail in an attempt to clarify their ability or inability to interact with the *hdp^2^* mutation. Each mutant accumulates substantial levels of MHC in adult thoraces: *Mhc* ^5^ homozygotes at 88% of wild-type levels, *Mhc^6^* homozygotes at nearly 100% ([@B19]), and *Mhc^8^/+* (which is recessive lethal) at 79% ([@B28]). *Mhc^6^* is a point mutation (Arg to His) in the rod of the myosin molecule ([@B19]). We determined molecular defects in the other two mutants by sequencing clones containing PCR-amplified copies of their *Mhc* genes. As suspected, these mutations result from single amino acid changes. In the case of *Mhc^5^*, amino acid 200 is mutated from a Gly to Asp (resulting from an A to G transition in exon 4). On the three-dimensional crystal structure, this residue is located near the base of loop 1 of the molecule, at the beginning of a long helix that appears to interact with the bound nucleotide (Fig. [2](#F2){ref-type="fig"}). Interestingly, the mutated amino acid in *Mhc^5^* is quite close to residue 261, which is mutated in suppressor strain *D45*. The *Mhc^8^* mutation is located in the region that binds regulatory light chain, at residue 832 (Fig. [2](#F2){ref-type="fig"}). The C to T mutation in exon 12 results in a change from Tyr to His. This portion of the molecule is part of the lever arm that is proposed to move during the myosin power stroke, due to pivoting about a point near the active site ([@B15]; [@B7]).

These three *Mhc* point mutations exhibit very different effects when tested in combination with the *D* mutations in a *hdp^2^* background (Table [III](#TIII){ref-type="table"}). *D1* is lethal when over *Mhc^5^*, but viable over the other two *Mhc* alleles and the deficiency chromosome (*Df(2)H20*). In contrast, *Mhc^8^* is lethal or poorly viable over *D41*, *D45,* or *D62,* but not over *D1*. The *Mhc^6^* mutation has no effect on viability in combination with suppressor mutations or on their ability to suppress heldup wing phenotype, except for a reduction in suppression with the *D45* allele.

Finally, we tested the troponin I allele specificity of heldup wing suppression by *D*-series mutations. We used *hdp^3^* or *hdp^2^*/*hdp^3^* as alternative backgrounds. The *hdp^3^* point mutation causes abnormal RNA splicing, resulting in failure of a specific subset of troponin I isoforms to accumulate in the indirect flight muscles ([@B2]). *hdp^3^* mutants display a paucity of thin filaments and severely disrupted myofibrils ([@B3]). We detected no suppression in *hdp^3^* or *hdp^2^*/*hdp^3^* backgrounds, indicating that *D*-series alleles suppress a specific molecular defect in *hdp^2^* mutation.

Taken together, our genetic studies demonstrate that suppression of the heldup wing phenotype in the *hdp^2^* point mutant can only result from specific modifications of MHC structure, as opposed to other perturbations in MHC structure or reductions in myosin concentration. Conversely, structural defects in DLMs caused by depletion of certain troponin I isoforms cannot be suppressed by these single amino acid changes in MHC.

Discussion {#Discussion}
==========

In this paper, we identified an unexpected interrelationship between myosin and troponin I through the use of a mutational screen for increased muscle function and integrity. We demonstrated that specific mutations in *Mhc* revert the heldup wings phenotype and muscle degeneration displayed by flies carrying the *hdp^2^* allele of troponin I. This reversion is allele specific, both for troponin I mutations and mutations in myosin, indicating that our approach identifies a novel type of functional interaction between the muscle proteins. Our data demonstrate that suppressive effects of *D*-series mutations do not arise simply from a reduction in myosin. This is based on accumulation of MHC in the mutant lines, as well as the failure of *Mhc* null mutations to suppress *hdp^2^*.

The role of the amino acid mutated in *hdp^2^* may be inferred from recent structural and functional studies on this region of the protein in vertebrate troponin I. The *hdp^2^* mutation affects the NH~2~-terminal α-helical portion of the protein shown to interact with troponin C ([@B10]; [@B47]; [@B21]; [@B50]). Rabbit skeletal muscle troponin I/troponin C cocrystal structure shows hydrophobic interactions between residue 25, which corresponds to the site of *hdp^2^* mutation, and troponin C ([@B50]). Although interaction between troponin I and troponin C appeared stable ([@B10]), the NH~2~-terminal fragment is now proposed to be released upon Ca^2+^ binding to troponin C ([@B47]; [@B50]). This release permits binding of an inhibitory domain of troponin I to troponin C, allowing the tropomyosin strand to move from its position blocking actin--myosin interaction. A reasonable model for *hdp^2^* defect is that the mutation hastens release of the α helix at lower Ca^2+^ concentrations, resulting in more ready binding of troponin I\'s inhibitory domain to troponin C. Unregulated actin--myosin interaction would result. The hypercontracted sarcomeres and muscle degeneration observed are consistent with this model (Fig. [1](#F1){ref-type="fig"}), as is the requirement for thick filaments for the degenerative phenotype ([@B3]).

The four suppressor alleles within the *Mhc* gene may identify specific molecular interactions between troponin I and myosin. Direct interaction between the troponin complex and the myosin head in insect flight muscle is structurally feasible, since antibody labeling of troponin complexes show they occur at some sites of rigor crossbridge attachment ([@B39]). Myosin interaction may occur directly with the wild-type troponin I residue identified by the *hdp^2^* mutation, perhaps aiding release of the surrounding α-helical region during Ca^2+^ binding by troponin C. This would facilitate actomyosin interactions, allowing the thin filament to progress to a fully active state. When poor regulation occurs in the *hdp^2^* mutant, the suppressor mutation could prevent or alter myosin interaction with the troponin I molecule. This would decrease the mutant troponin I\'s ability to release from troponin C, allowing the blocking action of troponin I on actomyosin interaction to continue at low Ca^2+^ concentrations. More normal muscle structure and function would result. Thus, while the troponin I mutation could alter the equilibrium among the three states of the thin filament proposed by [@B25] and [@B51], this equilibrium could be reestablished through a compensating mutation in the myosin head. The observation by [@B22], that troponin mutations can alter cycling of crossbridges, supports this possibility.

Direct interaction between mutated residues in troponin I and the myosin head is feasible for the residues identified by the *D62 Mhc* mutation. Biochemical ([@B29]; [@B44]), structural ([@B36],b), and chimeric molecule studies ([@B48]; [@B40]) indicate that residues deleted from the actin binding loop of MHC in mutation *D62* normally interact with the thin filament during the crossbridge cycle. For suppressor mutation *D1*, changes in orientation of the actin-binding loop could result from amino acid alteration at the loop\'s base. Instead of revealing a direct interaction between troponin I and MHC, *D1* or *D62* could affect crossbridge cycling and indirectly compensate for the troponin I mutation. The mechanism of action of these two suppressors may be similar. However, the synergistic effect of *D1* when combined with the other *D* suppressors, and the peculiar effect of *D1* in combination with other *Mhc* alleles (Table [III](#TIII){ref-type="table"}), suggests that this suppressor elicits a different, albeit unknown, functional change.

Direct interaction between the MHC regions identified by the other two suppressor mutations (*D41* and *D45*) and troponin I is not as obvious a possibility. However, it is important to realize that crystal structures of the myosin head represent static pictures of particular stages of the mechanochemical cycle. Thus, other contacts between thick and thin filaments are possible. A more likely explanation involves nucleotide exchange. Since both mutations are located near the nucleotide entry site of the molecule, it is reasonable to postulate that they would affect the ATPase cycle by regulating nucleotide entry or exit from the binding pocket ([@B30]; [@B45]). ADP release is the rate-limiting step in unloaded shortening of some muscles ([@B42]). If suppressor mutations reduce the rate of ADP release, myosin\'s dissociation from actin, which occurs upon subsequent binding of ATP, would be inhibited. This could dampen the unregulated actomyosin interactions that appear to occur in the *hdp^2^* mutant, since the ability of the myosin molecule to bind ATP and go through another step of the mechanochemical cycle would be reduced.

Another consideration for the mechanism of suppression is that myosin could act through a third protein to regulate troponin I. In this situation, troponin I would interact indirectly with myosin, through another protein or protein complex (such as tropomyosin or other components of the troponin complex). When troponin I has an abnormal interaction with this partner in the *hdp^2^* mutant, the partner is unable to productively interact with myosin, unless a specific interacting site (the location of the suppressor mutation) is altered. Actin is an obvious possibility for such an intermediary protein, since it interacts with the troponin/tropomyosin complex, as well as with myosin.

A key result of our study is that specific residues on MHC are required for suppression, suggesting they are critical to thick--thin filament interactions. None of the other alleles of *Mhc*, including point mutations, suppress the heldup wing phenotype (Table [III](#TIII){ref-type="table"}). This includes a mutation in the motor domain (*Mhc^5^*), a mutation in the lever arm (*Mhc^8^*), and a mutation in the rod (*Mhc^6^*). Interestingly, the genotype *hdp^2^*;*Mhc^5^/+* results in a lethal interaction (Table [III](#TIII){ref-type="table"}, and [@B16]). The location of this mutation close to the site of nucleotide entry/exit, and near *D41* and *D45* suppressors suggests that *Mhc^5^* might affect the ATPase cycle in the reverse direction of suppressors, thereby exacerbating rather than ameliorating the *hdp^2^* phenotypes. Support for this hypothesis is provided by the observation that lethality, but not heldup phenotype, of the *hdp^2^*;*Mhc^5^/+* genotype is eliminated when either the *D41*, *D45*, or *D62* suppressors replace the wild-type *Mhc* allele (Table [III](#TIII){ref-type="table"}). *D1* is an exception in rescuing lethality of the *hdp^2^*;*Mhc^5^* combination. In contrast, MHC of the *D1* type is compatible with *Mhc^8^* for viability, but this is not so with *D41*, *D45*, or *D62* (Table [III](#TIII){ref-type="table"}). The opposite effects of *D1* and other suppressor alleles strengthens our conclusion from suppressor heterozygote studies that *D1* MHC acts to suppress the *hdp^2^* phenotype by a different mechanism than other suppressors.

Our studies have implications for understanding disease processes in humans. In familial hypertrophic cardiomyopathy, single amino acid changes in a number of contractile proteins affect crossbridge cycling, resulting in myofibrillar disarray and hypertrophy ([@B46]; [@B52]). Mutations implicated in this disease include numerous defects in the myosin S1 domain ([@B38]) and in troponin I ([@B18]). Thus, mutations in both thick and thin filament components can have similar consequences upon human cardiac muscle structure and function. A confounding factor in understanding the basis of disease process, and predicting its severity, is that genetic background influences disease penetrance. Our observations in *Drosophila* indicate that mutations in other components of the contractile apparatus can either exacerbate or ameliorate muscle dysfunction, and could serve as a model for understanding influences of genetic background upon disease penetrance. Further, our findings suggest suppression of human diseases by a mutated version of a contractile protein might prove useful in developing therapeutic strategies.
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![Normal and *heldup^2^* mutant dorsolongitudinal muscles (DLM). (A) Diagram showing the six (a--f) DLM fibers in a sagittal view. Anterior is to the left, and dorsal is up. (B) Detail of a fibril showing a sarcomere between Z bands and including an M line. (C) Transverse view of a fibril showing the 1:6 array of thick to thin filaments. The square box has one thick filament in the center and six surrounding thin filaments in a hexagonal pattern. (D) Sagittal section of a *hdp^2^* male. Note the remnants of the six DLMs near their attachment sites. (E) Hypercontracted sarcomeres in which the M line is no longer detected. (F) Cross section of a mutant muscle in which only thick filaments are visible. Bar: (A) 250 μm; (B and E) 750 nm; (C and F) 120 nm; (D) 240 μm.](JCB9811046.f1){#F1}

###### 

Genetic and Molecular Properties of the D-series Suppressors and Other Mhc Alleles

  *Mhc* genotype      Lethal over *Mhc* null      Protein[\*](#TFI-150){ref-type="table-fn"}      Wild-type sequence                         Mutant sequence[‡](#TFI-152){ref-type="table-fn"}
  ---------------- -- ------------------------ -- -------------------------------------------- -- --------------------------------------- -- ---------------------------------------------------------------------
                                                                                                                                             
  *D1*                no                          73                                              Asp                                        Gly (aa 625)
                                                                                                  GAT                                        GGT
  *D41*               yes                         65                                              AspAspAlaGlu                               AspGluStop\-\-\--
                                                                                                  GATGATGCTGAG                               GATGA[GTAGCT]{.ul}GAG
                                                                                                                                             \[changes aa 328, creates stop codon, 5′ splice site (underlined)\]
                                                                                                                                             
  *D45*               yes                         85                                              Ala                                        Thr (aa 261)
                                                                                                  GCT                                        ACT
  *D62*               yes                         77                                              Gly[GlyArgGlyLysLysGlyGlyGly]{.ul}Phe      GlyPhe
                                                                                                  GGAGGTCGTGGCAAGAAGGGCGGTGGCTTC             GGCTTC
                                                                                                  (deletion in *D62* underlined)             (deletion of aa 638-645)
  *Mhc^5^*            no                          88                                              Gly                                        Asp (aa 200)
                                                                                                  GGT                                        GAT
  *Mhc^6§^*           no                          90-100                                          Arg                                        His (MHC rod)
                                                                                                  CGC                                        CAC
  *Mhc^8^*            yes                         79[‖](#TFI-155){ref-type="table-fn"}            Tyr                                        His (aa 832)
                                                                                                  TAC                                        CAC

 Protein levels of MHC standardized to actin levels and expressed as a percentage of wild-type MHC accumulation.  

 Chicken amino acid sequences given to allow localization on the chicken myosin S1 structure.  

Data from [@B19].  

 Protein accumulation data from [@B28].  

![Locations of mutations on the three-dimensional structure of the myosin head. The figure depicts a stereo-pair image of the atomic resolution structure of chicken myosin S1 ([@B37]) with regions encoded by *Drosophila* alternative exons and *Drosophila Mhc* mutations superimposed. The backbone of the heavy chain is yellow, the essential light chain is green, and the regulatory light chain is red. The location of the β-phosphate group of ATP is shown as a red sphere, with the reactive thiols depicted as tricolored residues. The *Drosophila* MHC regions encoded by alternative exons are purple (exon 3), light blue (exon 7), dark blue (exon 9), and tan (exon 11; [@B4]). Two *hdp^2^* suppressor mutations are at the actin binding loop. Mutation *D1* affects residue 625 at the base of the loop while mutation *D62* is an 8 amino acid deletion in the loop itself. The loop is not visible in the structure due to its flexible nature, but its ends are located behind residue 625 and at the terminus of a long helical structure just to its right. Mutation *D45* is at residue 261, on the surface of the molecule. This residue is just to the right of the two free ends of the molecule representing the flexible loop at the lip of the nucleotide binding pocket. The loop itself is not visible in the structure. Mutation *D41* affects the lip of the nucleotide pocket by causing the substitution of exon 7 alternative exons (light blue). Residue 200, which is mutated in *Mhc^5^*, is also in this general vicinity of the molecule and acts to enhance the effects of *hdp^2^*. A mutation in the regulatory light chain binding domain at residue 832 (*Mhc^8^*) enhances the effects of the *hdp^2^* allele to a lesser extent. Graphic produced in collaboration with Dr. Ronald Milligan (The Scripps Research Institute) using the Molscript program.](JCB9811046.f2){#F2}

![In situ hybridization analysis of *Mhc* mRNA accumulation in wild-type and *D41 Mhc* mutant. *D41* mutation creates a splice junction-like sequence resulting in misregulation of alternative splicing of the exon 7 series. Probes specific to alternative versions of exon 7 show that exon 7d is used in wild-type indirect flight muscles, but replaced with exon 7c in *D41*. Panels are brightfield micrographs of parasagittal sections of thoraces (anterior is left, dorsal is up). (A) Wild-type male probed with exon 7c, showing no hybridization to the indirect flight muscles that comprise the bulk of the upper thoracic region. (B) Wild-type male probed with exon 7d, showing strong hybridization to the indirect flight muscles. (C) *hdp^2^/Y*;*D41/Mhc^10^* males probed with exon 7c, showing strong hybridization to the indirect flight muscles. (D) *hdp^2^/Y*;*D41/Mhc^10^* males probed with exon 7d showing failure of the indirect flight muscles to hybridize with this probe.](JCB9811046.f3){#F3}

###### 

Suppression of the troponin I mutation *hdp^2^* by the *D*-series *Mhc* mutations. *D1* (A--D) and *D62* (E--H) affect the actin-binding loop of MHC. (A) Sagittal, slightly tilted, view of a *hdp^2^*;*D1/+* male. Note the almost normal appearance of DLM fibers a--d but the collapse of muscles e and f (arrow- head). (B) Detail of two fibrils. Note the restoration of the M line in the sarcomeres. (C) Cross section of a suppressed muscle. m = mitochondrion. (D) Detail of the thick--thin filament array. Some structural failures such as the absence of a thick filament (arrow- head) or an additional thin filament (arrow) can be identified. (E) Sagittal view of a *hdp^2^*;*D62/+* male. Note the persistence of gross structural defects on muscles e and f near the posterior attachment site. (F) Detail of fibrils showing virtually normal sarcomeres. (G) Cross section showing a near normal fibril. The apparent disorganization indicated by an arrowhead is an artifact of preparation, found occasionally in wild-type. (H) Detail of the filament array. *D41* (I--L) and *D45* (M--P) are mutations near the nucleotide entry site in MHC. (I) Sagittal view of a *hdp^2^*;*D41/+* male. There are persistent structural defects towards the posterior side of muscles e and f. (J) Detail of the fibrils. Note the incomplete definition of Z and M bands towards the edge of the fibril (double arrows). (K) Cross section of fibrils showing the disorganized array at the periphery (star). (L) Detail of the filament array. Occasionally, thick filaments are absent or a thin filament substitutes for thick (squares). (M) Sagittal section of an *hdp^2^*;*D45/+* male. As with all other suppressors, gross structural defects persist toward the posterior site of e and f muscle, although, in this case, d is also visibly affected. (N) Sarcomeres with incomplete restoration of Z and M lines. (O) Cross view of fibrils. (P) Detail of filament array showing a double thick filament (square). Bar: (A, E, I, and M) 330 μm; (B, F, J, and N) 775 nm; (C, G, K, and O) 430 nm; (D, H, L, and P) 144 nm.

![](JCB9811046.f4ah)

![](JCB9811046.f4ip)

###### 

Flight Ability Is Impaired by the D-series Suppressors and this Phenotype Is Not Rescued by an Additional Copy of the Mhc Gene

  *Mhc* genotype      Number tested      Direction of flight                      
  ---------------- -- --------------- -- --------------------- -- ---- -- ---- -- ----
                                                                                  
  +/+                 100                87                        3       7       3
  +/+/+               119                86                        8       4       2
  *D1/*+               60                70                       15      10       5
  *D1/*+/+            111                82                        8       5       5
  *D41/*+              57                32                       53       5      10
  *D41/*+/+           120                37                       34       8      21
  *D45/*+              90                67                       20       3      10
  *D45/*+/+            93                53                       22      15      10
  *D62/*+              72                 4                       12      42      42
  *D62/*+/+           177                 4                       20      34      42
  *Mhc^5^/*+          142                14                       44      18      24
  *Mhc^5^/*+/+        167                17                       37      23      23

![Double suppressor combinations. Longitudinal (A, C, and E) and transverse (B, D, and F) views of *D1/ D45* (A and B), *D1/D41* (C and D) and *D1/D62* (E and F) dorsolongitudinal muscles in males carrying the *hdp^2^* mutation. Note the improved restoration of muscle structure in cases of *D41* and *D45* combinations with *D1* suggesting independent and additive mechanisms of suppression. In the case of the *D1/ D62* combination, although there is an additional improvement in the restoration of sarcomere and filament array, there is a new structural feature: the frequent assembly of thick filaments in pairs. Bar: (A, C, and E) 775 nm; (B, D, and F) 144 nm.](JCB9811046.f5){#F5}

###### 

Interactions Between D Suppressors and other Mhc Mutations in hdp^2^ Males[\*](#TFIII-150){ref-type="table-fn"}

                  *Mhc^5^*        *Mhc^6^*        *Mhc^8^*                                        \+              *Df(2)H20*
  ------------ -- ------------ -- ------------ -- -------------------------------------------- -- ------------ -- ------------
  *D1*            Lethal          \+              hdp                                             \+              Viable
  *D41*           hdp             \+              Lethal[‡](#TFIII-152){ref-type="table-fn"}      \+              Lethal
  *D45*           hdp             50% hdp         Poorly viable                                   \+              Lethal
  *D62*           hdp             \+              Lethal[‡](#TFIII-152){ref-type="table-fn"}      \+              Lethal
  \+              Lethal          hdp             Poorly viable hdp                               hdp             hdp
  *Df(2)H20*      Viable/         Viable/         Lethal                                          Viable/         Lethal
                  flightless      flightless                                                      flightless      

 Minimum of 100 offspring per cross were screened.  

 Lethal also in females *hdp^2^*/*+*.  
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